Merck & Co Inc
NYSE:MRK 3:59:59 PM EDT
Products
Merck And Ridgeback Announce New Data For Investigational Molnupiravir From Phase 3 Move-Out Study
Published: 06/07/2022 11:14 GMT
Merck & Co Inc (MRK) - Merck and Ridgeback Announce New Data for Investigational Lagevrio™ (molnupiravir) From Phase 3 Move-out Study.
Merck - Based on Prespecified Endpoints, Lower Proportion of Participants Treated With Lagevrio Had Acute Care Visit Versus Those Who Received Placebo.
Merck - Based on a Post Hoc Analysis, Fewer Required Respiratory Interventions (including Invasive Mechanical Ventilation).
Merck - Based on Prespecified Endpoints, Lower Proportion of Participants Treated With Lagevrio Had Acute Care Visit Versus Those Who Received Placebo.
Merck - Based on a Post Hoc Analysis, Fewer Required Respiratory Interventions (including Invasive Mechanical Ventilation).